Deals this week: MyoKardia, Kala Pharmaceuticals, Mesoblast
MyoKardia has announced plans to issue more than nine million shares of its common stock priced at $13.3 a share, to raise $122.15m in gross proceeds.
Based in the US, MyoKardia is a biopharmaceutical company specialising in the development of therapies for cardiovascular diseases.
US-based pharmaceutical company Kala Pharmaceuticals has announced an initial public offering of six million common stock shares priced between $14 and $16 a share, to raise a minimum of $84m and a maximum of $96m.
Kala plans to use the funds towards the clinical development of its KPI-121 drug and for other general corporate purposes.
Australian regenerative medicine company Mesoblast has announced plans for a public offering of American Depositary Shares (ADS) to raise up to $180m.
Mesoblast plans to use the funds for general corporate purposes and to expand its business.
Evelo Biosciences has raised $50m through a Series B financing round that included participation from Flagship Pioneering, Google Ventures, Celgene, Mayo Clinic and Alexandria Venture Investments.
Based in the US, Evelo is a biotechnology company specialising in the development of cancer therapies. The funds will be utilised to advance the development of the company’s monoclonal microbial product candidates into clinical studies.
The product candidates are targeted at oncology and immuno-inflammatory diseases.